- Home
- AGIO vs RSI Comparison
AGIO vs RSI Comparison
Compare AGIO & RSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | RSI |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AGIO | RSI |
|---|---|---|
| Price | $30.08 | $22.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $37.63 | $23.00 |
| AVG Volume (30 Days) | 623.7K | ★ 1.5M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 933.33 |
| EPS | N/A | ★ 0.31 |
| Revenue | $43,011,000.00 | ★ $1,134,428,000.00 |
| Revenue This Year | $71.05 | $25.17 |
| Revenue Next Year | $163.65 | $14.08 |
| P/E Ratio | ★ N/A | $71.29 |
| Revenue Growth | N/A | ★ 22.76 |
| 52 Week Low | $22.24 | $9.66 |
| 52 Week High | $46.00 | $22.65 |
Technical Indicators
Market Signals| Indicator | AGIO | RSI |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 66.98 |
| Support Level | $26.48 | $20.70 |
| Resistance Level | $30.90 | $22.55 |
| Average True Range (ATR) | 0.97 | 0.87 |
| MACD | 0.10 | 0.08 |
| Stochastic Oscillator | 98.65 | 80.72 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About RSI Rush Street Interactive Inc.
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.